In the present study, combined treatment with etanercept and anakinra were tested in the streptozotocin-induced diabetic rats. Forty male Wistar albino rats were divided into 5 groups; healthy control (HC), diabetic control (DC), diabetic+anakinra (DAT), diabetic+etanercept (DET), and diabetic+etanercept+anakinra (DEAT). HC and DC groups received subcutaneous (sc.) injection with a saline solution, while DAT and DET groups received anakinra (10 mg/kg/day, sc.) or etanercept (10 mg/kg, twice a week, sc.), and DEAT rats received both anakinra and etanercept treatments for 21 days after diabetes has developed. Anakinra and etanercept treatments significantly increased insulin and homeostatic model assessment-β cell function levels and decreased glucose levels compared to the DC group as single (DAT and DET) and combined treatments (DEAT). The thiobarbituric acid reactive substances level was significantly decreased in DAT group. The combine use of etanercept and anakinra can improve insulin and blood glucose in type 2 diabetic rats. The combined treatment of anakinra and etanercept together was more effective than single treatment and might have a potential new treatment strategy and to reduce the mortality and morbidity resulting from diabetes.
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1.Introduction
Type 2 diabetes has now become one a serious worldwide public health problem (Selvaraju et al. 2012) . Diabetes is characterized by reduced insulin secretion or defects in insulin activity resulting in consistently high levels of blood glucose and requiring chronic treatment (Bas et al. 2012) . High blood insulin levels are found in the early stages of the disease due to increased resistance to insulin actions, which then develops into insulin dependent diabetes as the disease progresses. Hyperglycemia develops due to disrupted D r a f t secretion and increased insulin resistance results in glucotoxicity (Bas et al. 2012 ; Del Prato
2009; Maris et al. 2010).
Insulin resistance is a decreased physiological response to the normal effect of insulin.
There is a growing consensus in the literature that inflammation plays an important role in mediating glucotoxicity, insulin resistance, and other mechanisms underlying diabetes (Wellen and Hotamisligil 2003) . Chronically high glucose concentration results in coronary, cerebrovascular and peripheral vascular diseases, nephropathy, neuropathy, and retinopathy in long-term. For this purpose, the blood glucose level should be kept within normal limits 
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The dysfunction in β cells, the insulin secreting cells of the pancreas, is an important factor in the development of diabetes and can be promoted by diabetic hyperglycemia, macrophage infiltration, increased proinflammatory cytokines, and oxidative stress decreasing the capacity to secrete insulin (Akash et al. 2013 ). Depending on these factors, amyloid polypeptides are produced from the islets and these polypeptides interact with the inflammatory cells and cause inflammation in the pancreatic β islets (Donath and Halban 2004) .
High glucose and free fatty acid levels leads to increase activity of IL-1β, activation of nuclear factor kappa (NF-kB) pathway and develop endoplasmic reticulum stress, mononuclear cell infiltration and activation, and insulin-dependent disorders. After these events, expression of IL-1β, TNF-α which are proinflammatory cytokine and interferon gamma (IFN-γ) increase and apoptosis occur pancreatic β-cells. This chronic cycle leads to chronic inflammatory and organ damage, insulin resistance and insulin dependent patients 
2.Materials and Methods

Animals
A total of forty Wistar Albino rats of similar weights (200-250 g) for 6-10 weeks were used. Health checks were conducted before the rats were included in the study. Pellet rat diet (Bil-Yem Feeds, Ankara, Turkey) and water were provided ad libitum throughout the study.
The composition of diet given to healthy control (HC) group consisted of; dry matter: 89%, hp: 21%, cellulose: up to 5%, ash: up to 10%, Ca: 1-2%, P: 0.5-1%, NaCl: 0.5% 2850 kcal/kg.
Rats were housed in standard polypropylene cages in a controlled environment with automatic ambient humidity 55 ± 5%, a temperature of 22 ± 2°C, and a daily 12-h light/12 h dark cycle. 
Development of Experimental Type 2 Diabetes Model and Experimental Design
An experimental model of type 2 diabetes was induced in the rats following the method detailed by Srinivasan (Srinivasan et al. 2005 ). Rats were fed by high fat diet (HFD) containing 58% of total kcal as fat ad libitum for 2 weeks. HFD composition included 3% vegetable oil, 37% animal fat as tallow, 30.5% corn, 20% casein, 4.5% soy pulp, 1.7% dicalcium phosphate, 0.2% dl-methionine, 1.6% lime stone, 0.5% salt, and a vitamin-mineral blend 1%. Streptozotocin (STZ, ≥98% [HPLC], Sigma-Aldrich Co., USA) was dissolved in citrate buffer (pH 4.5, 20 mg/mL). After 2 weeks of HFD feeding, a subset of the rats was injected intraperitoneally (i.p.) with low dose STZ (35 mg/kg). Seven days after STZ injection, rats with the non-fasting glucose level of ≥300 mg/dl were considered as diabetic.
Rats were fed on HFD ad libitum until the end of the study. They were grouped as follows: and anakinra (10 mg/kg/day, s.c.) for 21 days.
At the end of the 21 days, blood samples were collected from the retro-orbital sinus of animals under thiopental Na anesthesia (40 mg/kg, i.p.) and rats were then euthanized by cervical dislocation.
Hematological, biochemical, endocrinological, oxidative status, and antioxidant capacity analysis
Hemogram parameters (erythrocyte, leukocyte, platelet, hematocrit, and hemoglobin) were analyzed using a blood cell counter (BC-2800 Auto Hematology Analyzer, Mindray Bio-Medical Electronics, Shenzen, China) with blood samples collected in anticoagulant tubes (K 2 EDTA). To generate serum samples blood was centrifuged at 1600 g and the serum 
Statistical Analysis
The distribution of values were tested for normality using SPSS 22.0 (SPSS, Inc., Chicago, IL, USA). Statistical significance among groups was tested using the Kruskal-Wallis and post hoc Mann-Whitney U test for parameters (diabetic and endocrinological parameters) that were not normally distributed and using one-way ANOVA for normally distributed parameters (other parameters) (SPSS 22.0) and posthoc Scheffe test. In all cases, p < 0.05 was considered statistically significant.
Results
The changes in diabetic parameters are presented in Table 1 after anakinra and etanercept treatment in experimental type 2 diabetic rats. Insulin was higher (p < 0.05) in DAT, DET, and DEAT groups than DC. DET and DEAT groups were similar to the HC group. Blood glucose level was significantly highest in the DC group when compared with the DAT, DET, and DEAT groups (p < 0.05). HbA1c level was higher (p < 0.05) in the DC group than HC group. HOMA-IR level were lower (p < 0.05) in the DEAT group than DC group D r a f t while HOMA-IR value of DEAT group was similar to HC group (Table 1) . HOMA-β value was higher (p < 0.05) in the treatment groups (DAT, DET and DEAT) than the DC group and the DC group was different from the HC group (Table 1) .
Adiponectin, resistin, and leptin levels remained unchanged between the experimental groups ( Table 2) .
Biochemical results of the study were variable (Table 3) . HDL was lowest in the DC group, while HDL levels were higher (p < 0.05) in the DET and DEAT. In addition, HDL level in DAET was similar in the HC group. Liver enzymes ALT and AST were lower (p < 0.05) in the DC group compared to the HC group. The cardiac injury marker CK-MB level was lower (p < 0.05) in the DEAT group than the HC and DC groups (Table 3) . RBC and hematocrit levels were higher (p < 0.05) in the DEAT group compared to the other groups (Table 4) . TAC was unchanged between the different groups (Fig 1) . In contrast, TBARS was lowest (p < 0.05) in DAT group compared to the DC group while the DET and DEAT groups were non-significantly lower than the DC group (Fig 2) .
Discussion
In the study, we confirmed that insulin secretion and HOMA-β levels decreased and HOMA-IR level increased in the DC group due to impaired β-cell function. While the decreased insulin levels were prevented by the anakinra treatment, etanercept was completely treated in DET and DEAT groups and the insulin levels was observed the same level with HC group. The HOMA-β levels were partially treated by anakinra or etanercept treatments alone, while the combination of both anakinra and etanercept (DEAT) restored HOMA-β to the same level as in the HC group (Table 1 In the study, glucose was significantly higher in the DC group than the other experimental groups (DAT, DET, DEAT, HC groups) and it statistically decreased in DAT, DET, DEAT groups (Table 1) . Unlike HbA1c levels were not change in the treatment groups than the HC group (Table 1) . Anakinra treatment in patients with type 2 diabetes can improve hyperglycemia by increasing insulin secretion capacity of β cells resulting in decreased TNF-α and IL-1, reducing both inflammation and hyperglycemia so potentially reducing reactive oxygen species and this may have partially reduced the TBARS level and increased the TAC level. However, lack of statistical differences in TBARS and TAC levels of treatment groups may be due to the short duration of the experiment.
In conclusion, treatment with etanercept and anakinra increases insulin and HOMA-β levels, while reducing glucose, HOMA-IR, and TBARS levels in this rat model of type 2 diabetes. These results indicate that anti-inflammatory therapy may have treated the insulin sensitivity and lowered the glucose level by inhibiting the inflammatory mechanism specifically at the cytokine level. As a result, the combined inhibition of both TNF-α and IL-1 is more effective than either treatment alone and the combination of etanercept and anakinra D r a f t D r a f t 
